questionText: To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients who would become eligible for treatment if Enhertu were recommended for routine commissioning by the NHS.
answerText: In July 2024, the National Institute for Health and Care Excellence (NICE) estimated that approximately 1,000 to 1,500 people would have been eligible for treatment with trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cance...
heading: Trastuzumab Deruxtecan